Clinical Trials Logo

Clinical Trial Summary

The main purpose of this study is to evaluate the long-term efficacy and safety outcomes following short-term exposure to rhIGF-1/rhIGFBP-3 versus standard neonatal care in Study ROPP-2008-01 (NCT01096784).


Clinical Trial Description

Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02386839
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 2
Start date March 26, 2015
Completion date September 28, 2021

See also
  Status Clinical Trial Phase
Terminated NCT04506619 - Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
Completed NCT04004208 - Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy Phase 3
Active, not recruiting NCT03253263 - A Clinical Efficacy and Safety Study of OHB-607 in Preventing Chronic Lung Disease in Extremely Premature Infants Phase 2
Withdrawn NCT01470430 - VEGF In Systemic Circulation Of ROP-infants N/A
Completed NCT01054027 - Study on Effective Mydriasis in Premature Infants N/A
Active, not recruiting NCT04015180 - Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 Phase 3
Completed NCT01096784 - IGF-1/IGFBP3 Prevention of Retinopathy of Prematurity Phase 2
Completed NCT02640664 - Rainbow Extension Study Phase 3
Completed NCT02134457 - Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity Phase 2
Terminated NCT01954082 - Inositol to Reduce Retinopathy of Prematurity Phase 3